Compounds of Formula I are antagonists of VLA-4 and/or 47,
and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion
mediated pathologies. These compounds may be formulated into pharmaceutical compositions
and are suitable for use in the treatment of asthma, allergies, inflammation, multiple
sclerosis, and other inflammatory and autoimmune disorders.